Replies to post #337677 on ORIONS Money Stocks

[$oldier Hard]

AMPE, yeah it does, about 20% of the float and a 5 yr high of $10.86 and that high was in the latter part of 2013

[JJSeabrook]

AMPE-$56M in cash as of their last Q filing.

[$oldier Hard]

AMPE yesterday...
Luoxis Establishes Initial European Distribution Network for RedoxSYS(TM) Diagnostic System
8:00a ET January 22, 2015 (PR NewsWire) Print

Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced it has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS(TM) Diagnostic System to prominent academic and pharma-based research centers within their respective territories. RedoxSYS is a first-in-class diagnostic platform and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress.

Under the terms of the agreements, Eurobio was granted territorial rights to offer RedoxSYS to institutions based in France and Switzerland, while Una Health Limited and THP Medical were granted territorial rights to the United Kingdom and Austria, respectively. These are multi-year agreements with the option to renew at the 3-5 year mark. As a whole, the customer base for Luoxis' initial EU distribution network includes notable research centers, such as The French National Centre for Scientific Research (CNRS), the French Institute of Health and Medical Research (INSERM), the National Institute of Agronomic Research (INRA), the National Centre for Veterinarians and Food Studies (CNEVA).

Josh Disbrow, Luoxis' President and Chief Executive Officer, stated, "We are excited to partner with these premier European distributors, who will introduce our novel RedoxSYS Diagnostic System to their esteemed customer base and potentially facilitate and accelerate ORP research and development. In line with our current strategy, we expect these agreements to result in high quality research studies using RedoxSYS that further support the clinical potential of ORP and the versatile applicability and broad utility of our RedoxSYS Diagnostic System."

About the RedoxSYS Diagnostic System: The RedoxSYS Diagnostic System is a first-in-class clinical diagnostic platform that measures oxidation-reduction potential (ORP) in the body, a homeostatic measurement of oxidative stress that changes in response to injury or illness. The result of nearly two decades of clinical, scientific and technical R&D, the RedoxSYS System is able to provide the only complete assessment of a patient's oxidative status, which has broad diagnostic application across multiple disease areas where oxidative stress is implicated. Luoxis is currently developing RedoxSYS as a simple, rapid blood test for use in the critical care setting, where its ability to provide an objective measurement of patient illness and predict potential complications may enable physicians to improve resource allocation and align higher levels of care with the most critically injured and ill patients, leading to improved outcomes and optimal workflows.